Media headlines about ABIOMED (NASDAQ:ABMD) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ABIOMED earned a news impact score of 0.24 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 46.3407448792584 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of ABIOMED (ABMD) traded down $1.61 during midday trading on Tuesday, reaching $187.96. The company’s stock had a trading volume of 379,090 shares, compared to its average volume of 340,166. The stock has a market cap of $8,380.00, a P/E ratio of 124.74, a price-to-earnings-growth ratio of 2.59 and a beta of 0.15. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.84 and a quick ratio of 5.20. ABIOMED has a 12 month low of $103.53 and a 12 month high of $200.28.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.16. The company had revenue of $132.80 million during the quarter, compared to the consensus estimate of $131.18 million. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. ABIOMED’s revenue for the quarter was up 28.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.20 EPS. equities analysts anticipate that ABIOMED will post 2.38 earnings per share for the current year.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price objective for the company in a research note on Tuesday, November 7th. SunTrust Banks reaffirmed a “buy” rating and issued a $195.00 price objective on shares of ABIOMED in a research note on Wednesday, November 1st. BTIG Research reaffirmed a “hold” rating on shares of ABIOMED in a research note on Sunday, October 29th. Piper Jaffray Companies lifted their price objective on ABIOMED to $200.00 and gave the company an “overweight” rating in a research note on Thursday, October 26th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $200.00 price objective (up from $180.00) on shares of ABIOMED in a research note on Thursday, October 12th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $185.38.

In other news, VP Andrew J. Greenfield sold 11,282 shares of ABIOMED stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $169.32, for a total transaction of $1,910,268.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Dorothy E. Puhy sold 6,364 shares of ABIOMED stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $179.08, for a total value of $1,139,665.12. Following the sale, the director now owns 39,532 shares in the company, valued at approximately $7,079,390.56. The disclosure for this sale can be found here. Insiders have sold a total of 27,646 shares of company stock valued at $4,836,333 over the last ninety days. 7.00% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect ABIOMED (ABMD) Stock Price” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-abiomed-abmd-stock-price/1746216.html.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Insider Buying and Selling by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.